| P2093 | author name string | Hans Tillmann | |
| | Natravis Cox | |
| P2860 | cites work | Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 |
| | Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication | Q28250131 |
| | Telbivudine versus lamivudine in patients with chronic hepatitis B | Q28261708 |
| | A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Q28266038 |
| | Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial | Q28301659 |
| | The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Q29616215 |
| | Chronic hepatitis B: update 2009 | Q29617409 |
| | Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group | Q31405858 |
| | Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 |
| | Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment | Q33969253 |
| | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 |
| | Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 |
| | Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 |
| | 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. | Q34600796 |
| | Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis | Q34615975 |
| | Epidemiology of hepatitis B in Europe and worldwide | Q35621655 |
| | Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study | Q35833000 |
| | Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. | Q53571993 |
| | Hepatitis B Virus Infection | Q54152887 |
| | Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. | Q54377204 |
| | Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients | Q57782730 |
| | Evolving strategies to prevent HBV recurrence. | Q35894616 |
| | Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. | Q36882276 |
| | EASL Clinical Practice Guidelines: management of chronic hepatitis B. | Q37340737 |
| | Endpoints of therapy in chronic hepatitis B. | Q37462552 |
| | Control of cccDNA function in hepatitis B virus infection. | Q37555389 |
| | Monotherapy versus combination therapy for the treatment of chronic hepatitis B. | Q37620354 |
| | Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. | Q37792970 |
| | Effect of conventional interferon-α in patients with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis | Q37846859 |
| | Lessons from maraviroc clinical trials | Q37892555 |
| | Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. | Q38428520 |
| | Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study | Q38501403 |
| | Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. | Q39943118 |
| | Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly | Q39954594 |
| | Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma | Q40276594 |
| | Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B | Q42004056 |
| | Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication | Q42740762 |
| | Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels | Q42947260 |
| | Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus | Q43041294 |
| | Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy | Q43102303 |
| | Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. | Q43187480 |
| | A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. | Q43208914 |
| | Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza | Q43209041 |
| | Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function | Q43235917 |
| | Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. | Q43435144 |
| | Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy | Q43629454 |
| | Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis | Q43680372 |
| | Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. | Q43695474 |
| | Hepatitis B e antigen and the risk of hepatocellular carcinoma | Q44068676 |
| | Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. | Q44079403 |
| | Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses | Q44116651 |
| | Fanconi syndrome and renal failure induced by tenofovir: a first case report | Q44235015 |
| | Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 |
| | Long-term safety of lamivudine treatment in patients with chronic hepatitis B. | Q44729211 |
| | A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly | Q44969179 |
| | Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 |
| | Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study | Q45383523 |
| | Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. | Q45385574 |
| | Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. | Q45396940 |
| | BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly | Q45411705 |
| | Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy | Q45742118 |
| | Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. | Q46176187 |
| | Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 |
| | A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients | Q46757241 |
| | A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 |
| | Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers. | Q48906218 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis B | Q6853 |
| P304 | page(s) | 713-729 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging pipeline drugs for hepatitis B infection | |
| P478 | volume | 16 | |